Senseonics Holdings news

The company successfully priced an $80 million public offering, demonstrating investor confidence and providing significant capital to fund the commercial launch of Eversense 365 and pipeline development. This capital infusion supports growth initiatives in the diabetes management market.

Listed among leading CGM companies in a market projected to nearly triple in value by 2034, benefiting from increased awareness and adoption of continuous glucose monitoring technology.

Company achieved significant milestones including European CE Mark approval, successful product launch in Sweden with additional markets planned, 72% year-over-year revenue growth in Q4 2025, and strategic partnership integration with Sequel Med Tech. The Eversense 365 represents a technological advancement with differentiated features and expanded addressable market of 30+ million patients.

Strong real-world clinical data demonstrating sustained performance of Eversense 365 over full year with high patient adherence (93.8% wear time) and positive glycemic outcomes (GMI 7.14%, TIR 66%). FDA approval achieved in September 2024, commercial launch in October 2024, and CE Mark approval in January 2026 with European expansion planned. Early AID combination data also shows promising results. Q4 2025 revenue increased 72% year-over-year.

The partnership expands Senseonics' Eversense 365 integration into a major AID platform, increasing adoption potential and market reach. The one-year sensor duration differentiates the product and creates value through broader ecosystem compatibility.

Key player in the continuous glucose monitoring segment, positioned to benefit from market growth driven by AI integration and home healthcare trends.

Presented strong real-world evidence for Eversense 365 with 93.8% wear time and consistent glucose management outcomes; received European CE Mark approval and plans launches in multiple countries, validating the year-long CGM technology.